Lu177‐ PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution
Author:
Affiliation:
1. Wesley Medical Imaging Brisbane Queensland Australia
Publisher
Wiley
Subject
Radiology Nuclear Medicine and imaging,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/1754-9485.12891
Reference22 articles.
1. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability‐adjusted life‐years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study;Fitzmaurice C;JAMA Oncol,2018
2. The changing therapeutic landscape of castration‐resistant prostate cancer;Yap TA;Nat Rev Clin Oncol,2011
3. Abiraterone and increased survival in metastatic prostate cancer;Bono JS;New Engl J Med,2011
4. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy‐naive men with metastatic castration‐resistant prostate cancer (COU‐AA‐302): final overall survival analysis of a randomised, double‐blind, placebo‐controlled phase 3 study;Ryan CJ;Lancet Oncol,2015
5. Management of patients with advanced prostate cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017;Gillessen S;Eur Urol,2018
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Low cost, high temporal resolution optical fiber-based γ-photon sensor for real-time pre-clinical evaluation of cancer-targeting radiopharmaceuticals;Biosensors and Bioelectronics;2024-03
2. Can VPAC-Targeted Cu-67-TP3805 Play a Theranostic Role for Prostate Cancer?: A Quest;Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum;2024
3. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT);European Journal of Nuclear Medicine and Molecular Imaging;2023-05-29
4. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review;Expert Review of Anticancer Therapy;2023-05-24
5. 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art;The Oncologist;2022-10-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3